Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk A/S (UK) (GB:0QIU)
:0QIU
0QIU Stock Chart & Stats
kr344.15
kr15.20(2.51%)
At close: 4:00 PM EST
kr344.15
kr15.20(2.51%)
Day’s Range― - ―
52-Week Rangekr287.55 - kr813.80
Previous CloseN/A
Volume862.13K
Average Volume (3M)1.26M
Market Cap
kr1.52T
Enterprise Valuekr2.04T
Total Cash (Recent Filing)kr41.55B
Total Debt (Recent Filing)kr118.72B
Price to Earnings (P/E)13.8
Beta1.13
Next Earnings
Nov 05, 2025EPS Estimate
4.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.96
Shares Outstanding3,390,128,000
10 Day Avg. Volume1,031,927
30 Day Avg. Volume1,260,758
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr439.75Price Target Upside27.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Market StrategyNovo Nordisk is proactively engaging with physicians to optimize dosing strategies, which could enhance the safety and tolerability profile of its products.
Product DevelopmentNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.
Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.
Bears Say
Financial PerformanceNovo announced an EBIT guide cut on restructuring costs, with the guide range lowered significantly, making the net benefit unclear.
Growth ChallengesThere is a lack of growth in prescription trends for Wegovy and Ozempic, with market pressure anticipated from patent expiry and competitor launches.
Sales OutlookThere is a risk of a top-end sales guide cut for FY25, with implications continuing into FY26, due to disappointing sales trajectories.
Novo Nordisk News
0QIU FAQ
What was Novo Nordisk A/S (UK)’s price range in the past 12 months?
Novo Nordisk A/S (UK) lowest share price was kr287.55 and its highest was kr813.80 in the past 12 months.
What is Novo Nordisk A/S (UK)’s market cap?
Novo Nordisk A/S (UK)’s market cap is kr1.52T.
When is Novo Nordisk A/S (UK)’s upcoming earnings report date?
Novo Nordisk A/S (UK)’s upcoming earnings report date is Nov 05, 2025 which is in 16 days.
How were Novo Nordisk A/S (UK)’s earnings last quarter?
Novo Nordisk A/S (UK) released its earnings results on Aug 06, 2025. The company reported kr5.96 earnings per share for the quarter, beating the consensus estimate of kr5.933 by kr0.027.
Is Novo Nordisk A/S (UK) overvalued?
According to Wall Street analysts Novo Nordisk A/S (UK)’s price is currently Undervalued.
Does Novo Nordisk A/S (UK) pay dividends?
Novo Nordisk A/S (UK) does not currently pay dividends.
What is Novo Nordisk A/S (UK)’s EPS estimate?
Novo Nordisk A/S (UK)’s EPS estimate is 4.98.
How many shares outstanding does Novo Nordisk A/S (UK) have?
Novo Nordisk A/S (UK) has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk A/S (UK)’s price movement after its last earnings report?
Novo Nordisk A/S (UK) reported an EPS of kr5.96 in its last earnings report, beating expectations of kr5.933. Following the earnings report the stock price went down -4.442%.
Which hedge fund is a major shareholder of Novo Nordisk A/S (UK)?
Currently, no hedge funds are holding shares in GB:0QIU
Company Description
Novo Nordisk A/S (UK)
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
0QIU Stock 12 Month Forecast
Average Price Target
kr439.75
▲(27.78% Upside)
Technical Analysis
Options Prices
Currently, No data available
---